• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型冠状病毒肺炎 - 这种疾病是否因病毒 ACE2 攻击引起的遗传和性别差异导致肾素血管紧张素系统（RAS）失衡而致死？

COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?

机构信息

Orange Health Service, Orange, NSW, Australia.

出版信息

Heart Lung Circ. 2020 Jul;29(7):964-972. doi: 10.1016/j.hlc.2020.05.004. Epub 2020 May 25.

DOI:10.1016/j.hlc.2020.05.004
PMID:32564908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7247492/
Abstract

Debate continues in the medical literature on the role of the renin angiotensin system (RAS) in Coronavirus disease 2019 (COVID-19) pathophysiology and the implications for the use of cardiovascular drugs acting on the RAS. Could these drugs - which include angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptors blockers (ARBs) - be harmful or potential key therapeutic agents in COVID-19? And, could potentially helpful measures be available and in plain view on the pharmacy shelf?

摘要

医学文献中一直存在争议，即肾素-血管紧张素系统（RAS）在 2019 年冠状病毒病（COVID-19）病理生理学中的作用，以及这些作用对心血管药物（作用于 RAS 的药物）的使用的影响。这些药物包括血管紧张素转换酶抑制剂（ACEIs）和血管紧张素受体阻滞剂（ARBs），它们在 COVID-19 中是有害的还是潜在的关键治疗药物？并且，在药店的货架上是否可以看到潜在的有用措施？

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe4d/7247492/0638560168f6/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe4d/7247492/355619f2aa43/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe4d/7247492/0638560168f6/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe4d/7247492/355619f2aa43/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe4d/7247492/0638560168f6/gr2_lrg.jpg

相似文献

1
COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?新型冠状病毒肺炎 - 这种疾病是否因病毒 ACE2 攻击引起的遗传和性别差异导致肾素血管紧张素系统（RAS）失衡而致死？
Heart Lung Circ. 2020 Jul;29(7):964-972. doi: 10.1016/j.hlc.2020.05.004. Epub 2020 May 25.
2
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
3
Covid-19: the renin-angiotensin system imbalance hypothesis.Covid-19：肾素-血管紧张素系统失衡假说。
Clin Sci (Lond). 2020 Jun 12;134(11):1259-1264. doi: 10.1042/CS20200492.
4
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.SARS-CoV-2 大流行和研究空白：了解 SARS-CoV-2 与 ACE2 受体的相互作用及其对治疗的影响。
Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020.
5
COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?新型冠状病毒肺炎与肾素-血管紧张素系统抑制：血管紧张素转换酶 2（ACE2）的作用-争议有何科学依据？
J Intern Med. 2020 Oct;288(4):410-421. doi: 10.1111/joim.13101. Epub 2020 Jun 8.
6
Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations.新型冠状病毒肺炎死亡率与肾素-血管紧张素系统之间是否存在关联？呼吁开展流行病学研究。
Clin Infect Dis. 2020 Jul 28;71(15):870-874. doi: 10.1093/cid/ciaa329.
7
A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.涉及 RAS 介导的缓激肽风暴的 COVID-19 的机械模型和治疗干预。
Elife. 2020 Jul 7;9:e59177. doi: 10.7554/eLife.59177.
8
ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.ACE2（血管紧张素转化酶 2）、COVID-19 以及大流行期间 ACE 抑制剂和血管紧张素 II（血管紧张素 II）受体阻滞剂的使用：儿科观点。
Hypertension. 2020 Jul;76(1):16-22. doi: 10.1161/HYPERTENSIONAHA.120.15291. Epub 2020 May 5.
9
SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis.严重急性呼吸综合征冠状病毒2型发病机制：肾素-血管紧张素系统失衡促进肺纤维化。
Front Cell Infect Microbiol. 2020 Jun 12;10:340. doi: 10.3389/fcimb.2020.00340. eCollection 2020.
10
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.SARS-CoV-2 与 ACE2：解决 ARB 和 ACEI 争议的生物学和临床数据。
EBioMedicine. 2020 Aug;58:102907. doi: 10.1016/j.ebiom.2020.102907. Epub 2020 Aug 6.

引用本文的文献

1
Understanding the genetic determinant of severity in viral diseases: a case of SARS-Cov-2 infection.了解病毒性疾病严重程度的遗传决定因素：以SARS-CoV-2感染为例。
Egypt J Med Hum Genet. 2020;21(1):77. doi: 10.1186/s43042-020-00122-z. Epub 2020 Dec 31.
2
Evaluation of NO-Sartans against SARS-CoV-2.NO-血管紧张素转换酶抑制剂（NO-Sartans）抗 SARS-CoV-2 的评价。
Curr Drug Discov Technol. 2024;21(6):e050324227669. doi: 10.2174/0115701638279362240223070810.
3
Association between single nucleotide polymorphism of human angiotensin-converting enzyme 2 gene locus and clinical severity of COVID-19.

本文引用的文献

1
Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.心血管疾病与 COVID-19：澳大利亚和新西兰共识声明。
Med J Aust. 2020 Aug;213(4):182-187. doi: 10.5694/mja2.50714. Epub 2020 Jul 31.
2
Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.SARS-CoV-2 受体 ACE2 基因表达和调控的个体差异。
Aging Cell. 2020 Jul;19(7). doi: 10.1111/acel.13168. Epub 2020 Jun 19.
3
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
人类血管紧张素转换酶2基因位点单核苷酸多态性与新型冠状病毒肺炎临床严重程度的关联
Egypt J Med Hum Genet. 2022;23(1):125. doi: 10.1186/s43042-022-00331-8. Epub 2022 Aug 23.
4
The Renin-Angiotensin System in COVID-19: Can Long COVID Be Predicted?新冠病毒感染中的肾素-血管紧张素系统：能否预测长期新冠症状？
Life (Basel). 2023 Jun 28;13(7):1462. doi: 10.3390/life13071462.
5
Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence.新型冠状病毒肺炎与凝血障碍的相互关系：病理生理学和临床证据。
Int J Mol Sci. 2023 May 18;24(10):8945. doi: 10.3390/ijms24108945.
6
Hospital and laboratory outcomes of patients with COVID-19 who received vitamin D supplementation: a systematic review and meta-analysis of randomized controlled trials.COVID-19 患者接受维生素 D 补充剂治疗的医院和实验室结局：随机对照试验的系统评价和荟萃分析。
Naunyn Schmiedebergs Arch Pharmacol. 2023 Apr;396(4):607-620. doi: 10.1007/s00210-022-02360-x. Epub 2022 Dec 12.
7
In Vitro Characterization of a Tissue Renin-Angiotensin System in Human Nucleus Pulposus Cells.人髓核细胞中组织肾素-血管紧张素系统的体外特性研究
Cells. 2022 Oct 28;11(21):3418. doi: 10.3390/cells11213418.
8
The Dysregulation of the Renin-Angiotensin System in COVID-19 Studied by Serum Proteomics: Angiotensinogen Increases with Disease Severity.血清蛋白质组学研究 COVID-19 中肾素-血管紧张素系统的失调：血管紧张素原随疾病严重程度增加。
Molecules. 2022 Apr 12;27(8):2495. doi: 10.3390/molecules27082495.
9
High Angiotensin-Converting Enzyme and Low Carboxypeptidase N Serum Activity Correlate with Disease Severity in COVID-19 Patients.高血管紧张素转换酶和低羧肽酶N血清活性与COVID-19患者的疾病严重程度相关。
J Pers Med. 2022 Mar 5;12(3):406. doi: 10.3390/jpm12030406.
10
The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression.维生素 D 补充对 COVID-19 患者死亡率和入住重症监护病房的影响。系统评价、荟萃分析和荟萃回归。
Diabetes Metab Res Rev. 2022 May;38(4):e3517. doi: 10.1002/dmrr.3517. Epub 2022 Jan 15.
血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与英国多地点急性医院信托的严重 COVID-19 感染无关。
Eur J Heart Fail. 2020 Jun;22(6):967-974. doi: 10.1002/ejhf.1924. Epub 2020 Jul 7.
4
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.非裔美国人 COVID-19 患者的肺部和心脏病理学：来自新奥尔良的尸检系列。
Lancet Respir Med. 2020 Jul;8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5. Epub 2020 May 27.
5
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
6
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
7
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
8
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
9
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.中国武汉因 2019 年冠状病毒病（COVID-19）感染而住院的高血压患者中，肾素-血管紧张素系统抑制剂与严重程度或死亡风险的关系。
JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624.
10
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.SARS-CoV-2 与肾素血管紧张素系统相互作用的临床意义：美国心脏病学会评论专题周报。
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.